Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin.

AIMS To investigate the influence of a multiple-dose regimen with the catechol-O-methyltransferase inhibitor entacapone on the pharmacokinetics and pharmacodynamics of warfarin. METHODS In a randomized, double-blind, two-way cross-over study, 12 healthy subjects (gender ratio 1 : 1) received treatment for 1 week with either entacapone 200 mg four times daily or placebo during individually optimized treatment with warfarin (INR 1.4-1.8). The effect of entacapone on the steady-state pharmacokinetics of both R- and S-warfarin was determined and, in addition, INR values were measured. The key pharmacokinetic variables were AUCss, Cmax and tmax. RESULTS Entacapone increased the exposure to R-warfarin by 18% (90% CI: 111, 126%), and caused a 13% (6, 19%) increase in INR values. No effect was seen on the pharmacokinetics of the pharmacologically more potent S-enantiomer. Safety and tolerability variables did not show any difference between the treatment phases. CONCLUSIONS In healthy subjects, entacapone displays a slight pharmacokinetic interaction with R-warfarin but, based on the lack of a clinically relevant pharmacodynamic interaction, it appears that it can also be used safely in Parkinson's disease patients who are receiving warfarin.

[1]  S. Frucht,et al.  An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines , 2002, Neurology.

[2]  O. Rascol,et al.  Continuous dopamine-receptor stimulation in early Parkinson's disease , 2000, Trends in Neurosciences.

[3]  J A Obeso,et al.  Preventing levodopa-induced dyskinesias. , 2000, Annals of neurology.

[4]  C. Colosimo.  The rise and fall of tolcapone , 1999, Journal of Neurology.

[5]  J. Larsen,et al.  Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations , 1998, Neurology.

[6]  P. Kaheinen,et al.  Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. , 1997, European journal of pharmacology.

[7]  Parkinson Study Group,et al.  Entacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patients , 1997, Annals of neurology.

[8]  J. Dingemanse.  Catechol‐O‐methyltransferase inhibitors: Clinical potential in the treatment of Parkinson's disease , 1997 .

[9]  S. Passe,et al.  The Effect of Orlistat on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers , 1996, Journal of clinical pharmacology.

[10]  P. Thürmann,et al.  Clinically Important Drug Interactions with Anticoagulants , 1996, Clinical pharmacokinetics.

[11]  V. Steinijans,et al.  Lack of pharmacokinetic interaction as an equivalence problem. , 1996, International journal of clinical pharmacology, therapy, and toxicology.

[12]  J. Hirsh,et al.  Interactions of Warfarin with Drugs and Food , 1994, Annals of Internal Medicine.

[13]  E. Chan,et al.  Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic‐pharmacodynamic model , 1994, Clinical pharmacology and therapeutics.

[14]  M. Grind,et al.  Method for studying drug‐warfarin interactions , 1993, Clinical pharmacology and therapeutics.

[15]  Malcolm Rowland,et al.  Population pharmacokinetics and pharmacodynamics of warfarin in healthy young adults , 1993 .

[16]  S. Kaakkola,et al.  Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. , 1990, Pharmacology & toxicology.

[17]  P. Höglund,et al.  Stereoselective Interaction of Omeprazole with Warfarin in Healthy Men , 1989, Therapeutic drug monitoring.

[18]  J. Nutt,et al.  Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients , 1987, Neurology.

[19]  B. Diquet,et al.  The warfarin-cimetidine interaction: stereochemical considerations. , 1986, British journal of clinical pharmacology.

[20]  M. Rowland,et al.  Stereospecific fluorescence high-performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine. , 1984, Journal of pharmaceutical sciences.

[21]  E. Chan,et al.  Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. , 1983, British journal of clinical pharmacology.

[22]  J. Mcewen,et al.  Plasma half‐lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man * , 1973, The Journal of pharmacy and pharmacology.

[23]  G G Koch,et al.  The use of non-parametric methods in the statistical analysis of the two-period change-over design. , 1972, Biometrics.

[24]  I. Lindén,et al.  Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat , 2001, Journal of Neural Transmission.

[25]  P. Pentikäinen,et al.  Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man , 2001, European Journal of Clinical Pharmacology.

[26]  J. Dingemanse.  Issues important for rational COMT inhibition. , 2000, Neurology.

[27]  J. Obeso,et al.  The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease. , 2000, Neurology.

[28]  J. Obeso,et al.  Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. , 2000, Neurology.